医学
感染性心内膜炎
精确检验
外科
对数秩检验
方差分析
入射(几何)
心内膜炎
生存分析
B组
卡方检验
内科学
数学
统计
光学
物理
作者
Liqun Jia,Qiang Fu,Shuai Yang,Degang Liang,Minxin Wei
出处
期刊:Chinese Journal of Thoracic and Cardiovaescular Surgery
日期:2012-08-25
卷期号:28 (08): 464-466
被引量:1
标识
DOI:10.3760/cma.j.issn.1001-4497.2012.08.005
摘要
Objective The surgery time for patients with infective endocarditis (IE) has been transformed.It has been supported that,for the patients with surgical indications,the surgery time should be as early as possible to improve the clinical outcome.The purpose of the research is to identify whether the patients with IE could get further benefit from early surgery.Methods Between June 1996 and July 2011,135 IE patients'data has been collected retrospectively,all of whom were verified through the modified Duke categories.The patients were devided into group A( the new therapeutic schedule group after 2008 ) and group B( the traditional therapeutic schedule group before 2008 ) by the year of 2008.The end points of observation were death associated with IE,cardiac failure,embolism,and re-infection.The comparison between the groups was by means of non-parameter rank and inspection test,variance analysis,t test,chi-square test,fisher exact test.The outcome comparison between the groups was via the Kaplan-Meier survival analysis.Results There were no significant differences in baseline data between the groups.No survival differences could be observed via the Kaplan-Meier analysis( Log Rank P =0.189).During the following-up visit,compared with the patients in group B,the mortality in group A is lower(9.4% vs.23.0%,P=0.016),the incidence of heart failu re was less in group A (5.4% vs.26.2%,P <0.001 ).No differences could be found in re-infection between the two groups(0 vs.4.9%,P =0.112 ). More patients in group A underwent surgery (67.6% vs.32.8%,P <0.001 ).Conclusion The new therapeutic sehedule of IE coull reduce the mortality rate and promote the cardiae funetion.The incidence of re-infeetion didn't increase.
Key words:
Endocarditis heart valve; Prosthesis implantation; Follow-up; Studies risk assessment
科研通智能强力驱动
Strongly Powered by AbleSci AI